Gyre Therapeutics Posts $32.9 Million in Q3 Revenue, $0.04 GAAP Loss Per Share

Gyre Therapeutics, Inc. posted $32.9 million in third-quarter revenue, up 0.6% from a year earlier, and recorded a GAAP loss per share of $0.04. The company maintained its 2026 revenue guidance at $100.5 million to $111 million. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Source: TokenPost